Showing results (411-420 of 763) with videos related to
Sort By:
Pageof 77
Journal of the American Society of Nephrology : JASN|March 21, 2008
Role of remission clinics in the longitudinal treatment of CKDPiero Ruggenenti, Elena Perticucci, Paolo Cravedi, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress reportLuca Antiga, Marina Piccinelli, Giorgio Fasolini, et al.Frontiers in Pharmacology|September 19, 2022
Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndromeAnnalisa Perna, Barbara Ruggiero, Manuel Alfredo Podestà, et al.Journal of the American Society of Nephrology : JASN|October 29, 2014
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKDGerald Schulman, Tomas Berl, Gerald J Beck, et al.Journal of the American Society of Nephrology : JASN|April 9, 2016
Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney DiseaseTobias F Kröpelin, Dick de Zeeuw, Giuseppe Remuzzi, et al.Kidney International|August 8, 2002
Effect of angiotensin II antagonism on the regression of kidney disease in the ratAndrea Remuzzi, Elena Gagliardini, Chiara Donadoni, et al.Lancet (London, England)|March 7, 2002
Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trialRaul Plata, Arturo Cornejo, Carla Arratia, et al.American Journal of Nephrology|August 31, 2011
Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritisAlessandro Ble, Marta Mosca, Giorgio Di Loreto, et al.Journal of the American Society of Nephrology : JASN|October 7, 2004
Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuriaAriela Benigni, Daniela Corna, Carla Zoja, et al.Clinical and Experimental Nephrology|July 26, 2017
Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120Gerald Schulman, Tomas Berl, Gerald J Beck, et al.Pageof 77